If you haven’t yet participated in the poll, we invite you to share your views on Chemo-Immunotherapy for CLL:
Excluding patients with del(17p)/TP53 mutation, which patients should be receiving chemo-immunotherapy firstline for CLL today?
- None – every patient should be receiving novel agents firstline today
- Only young, fit with mutated IgVH who are eligible for curative-intent FCR
- All patients except young and fit with unmutated IgHV
- All patients firstline